Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones

Arefhosseini, Sara; Ebrahimi-Mameghani, Mehrangiz; Najafipour, Farzad; Tutunchi, Helda

doi:10.3389/fendo.2022.1032361

Cited by 13 publications

(8 citation statements)

References 208 publications

(374 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous research has demonstrated that there were significantly more females than males with MAFLD in age subgroups older than 40 years and there was a sharp rise in the prevalence of MAFLD in perimenopausal and postmenopausal women 26 , 27 , a period during which the decrease in oestrogen levels can lead to fat redistribution and lead to metabolic disorders, including MAFLD 28 . Furthermore, abdominal obesity in women is a well-documented risk factor for polycystic ovary syndrome(PCOS) while a number of studies have suggested the close correlation between PCOS and NAFLD 29 . A meta-analyze involving 7148 participants has reported that premenopausal PCOS patients are associated with 2.5-fold increase in the risk of NAFLD 30 .…”

Section: Discussionmentioning

confidence: 99%

Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study

Cen,

Fan,

Ding

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD) present notable health challenges, however, abdominal obesity has received scant attention despite its potential role in exacerbating these conditions. Thus, we conducted a retrospective cohort study using the National Health and Nutrition Examination Surveys III (NHANES III) of the United States from 1988 to 1994 including 9161 participants, and mortality follow-up survey in 2019. Statistical analyze including univariable and multivariable Logistic and Cox regression models, and Mediation effect analyze were applied in study after adjustment for covariates. Our findings revealed that individuals with both abdominal obesity and MAFLD were more likely to be female, older and exhibit higher prevalence of advanced liver fibrosis (7.421% vs. 2.363%, p < 0.001), type 2 diabetes mellitus (T2DM) (21.484% vs. 8.318%, p < 0.001) and CKD(30.306% vs. 16.068%, p < 0.001) compared to those with MAFLD alone. MAFLD (adjusted OR: 1.392, 95% CI 1.013–1.913, p = 0.041), abdominal obesity (adjusted OR 1.456, 95% CI 1.127–1.880, p = 0.004), abdominal obesity with MAFLD (adjusted OR 1.839, 95% CI 1.377–2.456, p < 0.001), advanced fibrosis(adjusted OR 1.756, 95% CI 1.178–2.619, p = 0.006) and T2DM (adjusted OR 2.365, 95% CI 1.758–3.183, p < 0.001) were independent risk factors of CKD. The abdominal obese MAFLD group had the highest all-cause mortality as well as mortality categorized by disease during the 30-year follow-up period. Indices for measuring abdominal obesity, such as waist circumference (WC), waist-hip ratio (WHR), and lipid accumulation product (LAP), elucidated a greater mediation effect of MAFLD on CKD compared to BMI on CKD (proportion mediation 65.23%,70.68%, 71.98%, respectively vs. 32.63%). In conclusion, the coexistence of abdominal obesity and MAFLD increases the prevalence and mortality of CKD, and abdominal obesity serves as a mediator in the association between MAFLD and CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study

Cen,

Fan,

Ding

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In addition, a number of dysregulations of endocrine axes (hypothyroidism, growth hormone deficiency, hypercortisolemia, etc.) are associated with NAFLD/fibrosis development and progression [96,97]. There are some suggestions that thyroid hormone levels are associated with the risk of progressive hepatic fibrosis in patients with T2DM, NAFLD, and normal thyroid function [98].…”

Section: Factors Associated With Fibrosis Progression and Regressionmentioning

confidence: 99%

NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay

Cernea

2024

Life

View full text Add to dashboard Cite

The bidirectional relationship between type 2 diabetes and (non-alcoholic fatty liver disease) NAFLD is indicated by the higher prevalence and worse disease course of one condition in the presence of the other, but also by apparent beneficial effects observed in one, when the other is improved. This is partly explained by their belonging to a multisystemic disease that includes components of the metabolic syndrome and shared pathogenetic mechanisms. Throughout the progression of NAFLD to more advanced stages, complex systemic and local metabolic derangements are involved. During fibrogenesis, a significant metabolic reprogramming occurs in the hepatic stellate cells, hepatocytes, and immune cells, engaging carbohydrate and lipid pathways to support the high-energy-requiring processes. The natural history of NAFLD evolves in a variable and dynamic manner, probably due to the interaction of a variable number of modifiable (diet, physical exercise, microbiota composition, etc.) and non-modifiable (genetics, age, ethnicity, etc.) risk factors that may intervene concomitantly, or subsequently/intermittently in time. This may influence the risk (and rate) of fibrosis progression/regression. The recognition and control of the factors that determine a rapid progression of fibrosis (or its regression) are critical, as the fibrosis stages are associated with the risk of liver-related and all-cause mortality.

show abstract

“…NAFLD is considered as an umbrella term that includes different types of fatty liver diseases unrelated to alcohol consumption [ 4 ]. Due to the metabolic roots of NAFLD, it has been recently proposed that to rename NAFLD as metabolic dysfunction-associated fatty liver disease or 'MAFLD' [ 5 ]. A recent systematic review and meta-analysis through the extraction of available epidemiological data on fatty liver disease demonstrated that MAFLD has an astonishingly high prevalence rate in overweight and obese adults [ 6 ] .…”

Section: Introductionmentioning

confidence: 99%

The effect of DASH diet on glycemic response, meta-inflammation and serum LPS in obese patients with NAFLD: a double-blind controlled randomized clinical trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background As dietary approaches to stop hypertension (DASH) dietary pattern has been shown to be effective in hypertension and obesity, the present study investigated the effects of following DASH diet on glycemic, meta-inflammation, lipopolysaccharides (LPS) and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD). Methods In this double-blind controlled randomized clinical trial, 40 obese patients with NAFLD were randomly allocated into either “DASH diet” (n = 20) or calorie-restricted diet as "Control” (n = 20) group for 8 weeks. Anthropometric measures, blood pressure, glycemic response, liver enzymes, toll-like reseptor-4 (TLR-4) and monocyte chemoattractant protein (MCP-1) and LPS as well as Dixon's DASH diet index were assessed at baseline and after 8 weeks. Results After 8 weeks, although all obesity indices decreased significantly in both groups, the reduction in all anthropometric measures were significantly greater in DASH vs control group, after adjusting for baseline values and weight change. Fasting glucose level decreased in both group, however, no inter-group significant difference was found at the end of study. Nevertheless, serum levels of hemoglobin A1c (HbA1c), TLR-4, MCP-1 and LPS as well as aspartate aminotransferase (AST) decreased significantly in DASH group, after adjusting for baseline values and weight change (p < 0.001, p = 0.004, p = 0.027, p = 0.011, and p = 0.008, respectively). The estimated number needed to treats (NNTs) for one and two grade reductions in NAFLD severity following DASH diet were 2.5 and 6.67, respectively. Conclusion Adherence to DASH diet could significantly improve weight, glycemia, inflammation and liver function in obese patients with NAFLD.

show abstract

Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones

Cited by 13 publications

References 208 publications

Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study

Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study

NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay

The effect of DASH diet on glycemic response, meta-inflammation and serum LPS in obese patients with NAFLD: a double-blind controlled randomized clinical trial

Contact Info

Product

Resources

About